Loading clinical trials...
Loading clinical trials...
An Open-label, Single Sequence, Crossover Drug-drug Interaction Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of CYP3A4 and CYP2C9 Substrates in Patients
Conditions
Interventions
Tolbutamide
Midazolam
+1 more
Locations
11
United States
HonorHealth
Scottsdale, Arizona, United States
University of Arizona
Tucson, Arizona, United States
Stanford University
Palo Alto, California, United States
University of Kansas Cancer Center
Westwood, Kansas, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Karmanos Cancer Center
Detroit, Michigan, United States
Start Date
February 26, 2018
Primary Completion Date
September 26, 2018
Completion Date
April 16, 2021
Last Updated
May 14, 2021
Lead Sponsor
Daiichi Sankyo
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions